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ABSTRACT 
Background: Tumour-infiltrating lymphocytes (TILs) in breast cancer (BC) confer prognost-
ic and predictive information. This study aims to assess the spatial and temporal heterogen-
eity of TILs in BC and its relationship with immune cell subtypes.  
Method: Immunohistochemically-defined immune cell subtypes; T-cell markers (CD3, CD8, 
and FOXP3), B-cell marker (CD20) and histiocytic marker (CD68) were evaluated in a large 
series (n=1,165) of invasive BC.  A subset of full-face haematoxylin and eosin (H&E) stained 
slides were examined for TILs heterogeneity within primary tumours and the corresponding 
local recurrent carcinomas to report on spatial and temporal TILs heterogeneity. H&E stained 
sections from multiple tumour blocks (3-4 blocks per case) representing different tumour 
areas were evaluated to assess TILS inter-slide heterogeneity as well as intra-slide heterogen-
eity.  Both average (AV-TILs) and hotspot (HS-TILs) stromal TILs were assessed.  
Results: AV-TILs showed association with all immune cell subtypes however; the main com-
ponent were CD3+ cells (mean number = 55) whereas CD20+cells comprised the least com-
ponent (the mean number = 13). There was no significant statistical difference between TILs 
across tumour blocks of the same case (p=0.251 for AV-TILs and p=0.162 for HS-TILs). 
Triple negative breast cancer (TNBC) showed higher TILs compared with other BC subtypes 
(p<0.001). High AV-TILs, CD3+, CD8+, and CD20+ cells were associated with longer sur-
vival in TNBC (p<0.05). High AV-TILs in recurrent tumours showed significant association 
with shorter post-recurrence survival (p=0.004).  
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Conclusion: Despite the heterogeneity of immune cell type components, average TILs in one 
full-face H&E stained section reliably represent whole tumour TILs. TILs were associated 
with outcome in TNBC as well as provided prognostic significance in recurrent tumour. 
Keywords: breast cancer, TILs, outcome, heterogeneity  
Running title: TILs heterogeneity in breast cancer 
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INTRODUCTION 
Breast cancer (BC) microenvironment comprises a complex mixture of cell types including 
immune modulating cells that provide an opportunity for therapeutic modulation 1, 2. Several 
studies have reported prognostic and predictive roles of tumour infiltrating lymphocytes 
(TILs) in BC as assessed on haematoxylin and eosin (H&E) stained sections regardless of 
their cellular subtypes 3-6 and guideline recommendations to standardise TILs assessment in 
BC have been published 7. However, the impact of TILs heterogeneity, with variable TILs 
density and components in different tumour areas within BC subtypes remains to be defined. 
Various TILs subtypes have different roles in tumour progression either suppressing tumour 
growth by destroying cancer cells or promoting tumour progression by selecting those tu-
mour cells that could survive in an immunocompetent host 8-10. For instance, T-lymphocytes, 
which account for the majority of TILs in invasive BC, can activate host defense mechanisms 
9 mainly through cytotoxic CD8+ T-cells. However, T regulatory cells (T-reg) play a vital role 
in immune tolerance to tumour cells and can protect against tumour development and pro-
gression 10-12. The contribution of each immune cell subtype to the prognostic value of overall 
TILs assessed on H&E slides also remains unclear. In addition, the role of histiocytes, as a 
component of the immune cells in BC, and whether they contribute prognostic value and 
should be included in TILs assessment in BC has not been resolved. 
This study aims to investigate i) the TILs infiltrate in invasive BC and its spatial distribution 
and relate this to prognostic parameters and patient outcome in primary and recurrent tu-
mours.  ii) Contribution of various immune cell subtypes, as molecularly defined, to overall 
TILs and their prognostic value were also evaluated. 
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MATERIALS AND METHODS  
Study cohort 
The study cohort comprised 1,165 invasive BCs derived from the retrospective Nottingham 
Primary Breast Carcinoma Series of patients presenting to Nottingham City Hospital between 
1988 to 1998. Immunohistochemical detection of a panel of T lymphocytes markers includ-
ing pan T-cell CD3, cytotoxic T-cell CD8, T-reg FOXP3, B-cell CD20, and Histiocytic cell 
marker; CD68 were previously performed 13-15. Full-face H&E stained sections from a subset 
of cases (n=230) were used to assess TILs infiltration as well as intra-slide heterogeneity. 
Moreover, to assess inter-slide TILs heterogeneity, H&E stained slides from multiple forma-
lin fixed paraffin embedded (FFPE) archival tissue blocks (3-4 blocks/case) were prepared 
from a sub-group of cases (n=52/230). Patients’ clinical and pathological data including age 
at presentation, histological tumour type, primary tumour size, axillary lymph node status, 
histological tumour type, Nottingham Prognostic Index (NPI), Lymphovascular Invasion 
(LVI) and adjuvant chemotherapy were available. Biological data on expression of ER, PgR, 
HER2, EGFR, androgen receptor (AR) and basal cytokeratins (CK5/6 and CK14) was also 
available 16, 17. The data on HER2 was already available in this early-stage breast cancer co-
hort and details of staining and scoring were included in previous publications20-23. Survival 
data was prospectively maintained including 1) breast cancer-specific survival (BCSS), de-
fined as the time (in months) from the date of primary surgical treatment to the time of death 
from BC and 2) distant metastasis free survival (DMFS), defined as the time from the surgery 
until the first event of distant metastasis. In this study, post recurrence survival was defined as 
the time (in months) from the date of surgical removal of the recurrent tumour to the date of 
death from BC. Of the recurrent cases, 44 patients had a local recurrence tumour tissue avail-
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able and these were used to compare TILs distribution between primary and corresponding 
recurrent tumour. 
This study was approved by the Nottingham Research Ethics Committee 2 under the title 
“Development of a molecular genetic classification of breast cancer”. 
Immunohistochemistry and Immunoscoring  
The total number of each immune cell type and histiocyte were counted in the stroma sur-
rounding the tumour in each core. Supplementary table 1 shows the details of the different 
antibodies which were used.       
TILs assessment on H&E stained sections 
All tumour specimens were routinely fixed in 10% formalin and embedded in paraffin. Full-
face, 4µm sections were prepared for H&E staining and evaluated for stromal TILs.  All cases 
contained adequate tumour burden with at least 40% of the section surface area in each slide. 
H&E slides were scanned into high-resolution digital images at 20x magnification using 3D 
Histech Panoramic 250 Flash II scanner (3DHISTECH Ltd., Budapest, Hungary). The digital 
images were viewed using the 3D Histech Panoramic Viewer (3DHISTECH Ltd., Budapest, 
Hungary). TILs were semi-quantitatively assessed following the recommended method of the 
2014 International TILs Working Group 7. Each section was first scanned using low magnifi-
cation and the regions of interest located within the invasive tumour borders in the stromal 
compartment; around and dispersed in the intervening stroma between carcinoma cells but 
not directly contacting tumour cells.  TILs around crush artefacts, tumour necrosis, extensive 
central regressive hyalinisation, or DCIS/normal lobules were not considered for quantifica-
tion. All mononuclear cells, lymphocytes, histiocytic cells, and plasma cells, if any, were 
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scored and recorded as a percentage of TILs. The quantity of TILs was evaluated by the per-
centage of TILs occupied in the stroma (average TILs; AV-TILs). For further quantification of 
the pattern of TILs infiltrate, the presence of areas with dense TILs infiltrate were further de-
termined and designated as ‘Hotspots-TILs’ (HS-TILs). HS-TILs was defined as a cluster of 
lymphocytes densely containing the highest number of lymphocytes which is typically more 
than that of the overall/average stromal TILs. HS-TILs was equal to AV-TILs only in the cas-
es showing no or occasional scattered lymphocytes or in rare cases showing dense lympho-
cytic infiltration throughout the tumour. The highest area of TILs density was considered as 
the HS and was introduced to study intra-slide as well as inter-slides TILs heterogeneity. For 
assessment of intra-slide heterogeneity, annotation of each digital image was performed by 
dividing the tumour area into four quadrants using a vertical and horizontal line. AV-TILs and 
HS-TILs were assessed in each quadrant separately in addition to the whole slide. All cases 
were scored independently by two observers (M. Althobiti and C. Joseph), blinded to 
histopathological data and patients’ outcome. The observers were trained by a consultant 
pathologist (ER). Further, to test for the intra-observer reproducibility of our scoring system, 
50% of the cases were randomly selected and rescored by the same scorer.  
STATISTICAL ANALYSIS 
Intra-observer agreement was determined using Pearson correlation coefficient whereas inter-
observer agreement was determined using intra-class correlation coefficient. TILs scores 
were categorised using a 10% cut-off with scores <10% defined as negative/low whereas 
cases with scores ≥10% were defined as positive/high 18.  In recurrent tumours, the median 
percentage of TILs scores (5%) was used. Positive immunoreactivity for CD3, CD8, CD20, 
FOXP3, and CD68 were defined as previously described 13-15, 19. The association between the 
categorical groups of TILs density and clinico-pathological parameters were analysed using 
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Chi-square test. Spearman rank correlation co-efficient was used to assess the relationship 
between TILs and immune cell subtypes. Friedman and Kendall’s test was used for testing 
TILs expression between four slides (inter-slide heterogeneity) and in four quadrants (intra-
slide heterogeneity). Association with patient outcome was assessed using Kaplan-Meier and 
log-rank test. Cox proportional hazards regression models were built for multivariate survival 
analyses to estimate the hazard ratio (HR) of TILs and immune cell subtypes adjusted by oth-
er established prognostic factors. A p-value of less than 0.05 (two- tailed) was considered 
significant in all statistical tests.   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RESULTS 
Immune cell subtypes and TILs 
In the study cohort, 74.7% of the tumours were ER positive, 59% were PR+ positive and 
9.3% were HER2 positive.  To assess specific sub-population of TILs, the expression of lym-
phocytic biomarkers; CD3, CD8, CD20, and FOXP3 and macrophage/histiocytic biomarker; 
CD68 were evaluated in the whole cohort (n=1,165). Supplementary Table 2 shows the dis-
tribution of immune subtypes within different molecular classes. This revealed that the T-
lymphocyte population, as demonstrated by pan-T (CD3+ cells), was the main component of 
TILs followed by macrophages (CD68+ cells), while B-lymphocytes (CD20+ cells), com-
prised the least common component. Among T-lymphocytes, the overall contribution of 
CD8+ cells was more frequent than FOXP3+ cells. Despite the increased number of all im-
mune cells components in TNBC, the ratio of each subtype appeared similar across the whole 
series with the CD3+ cell population being the main contributing component (Figure 1). 
Univariate survival analysis demonstrated that high FOXP3+ and CD68+ counts were associ-
ated with shorter BCSS in all BC subtypes (p=0.006 and p<0.001, respectively; Supplemen-
tary Figures 1). However, high CD20+ cells showed a trend toward longer BCSS (p=0.066)  
High CD3+ (p=0.021, p=0.011), CD8+ (p=0.017, p=0.012), and CD20+ cells infiltrate 
(p=0.037, p=0.045) were associated with longer BCSS and DMFS respectively in TNBC 
(Supplementary Figures 2A-C). Dense histiocytic CD68+ cells were associated with shorter 
BCSS in luminal B tumours (p=0.04). High CD20+ infiltrate was associated with better 
BCSS in HER2 positive tumours (p=0.04) (Supplementary Figures 3A&B respectively). 
Cox-proportional models including patient age, tumour grade, nodal stage and different im-
mune cell subtypes showed only high CD8+ (p=0.002, HR 0.5, 95%CI 0.3– 0.8) and high 
CD3+ (p=0.003, HR 0.3, 95%CI 0.2– 0.7) lymphocytic infiltrates were independent predic-
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tors of improved outcome in TNBC while CD20+, CD68+ and FOXP3+ cells were not sig-
nificantly associated with outcome (supplementary table 3).  
TILs morphological heterogeneity 
We observed high reproducibility of TILs scoring by the same observer (Pearson correlation 
coefficient: 0.93 for AV-TILs and 0.97 for HS-TILs), and between the two observers (intra-
class correlation coefficient: 0.79 for AV-TILs and 0.83 for HS-TILs) and (kappa agreement: 
0.825 for AV-TILs and 0.785 for HS-TILs) using the methodology adopted in this study 7. 
Inter-observer agreement was determined using intra-class correlation coefficient for the four 
slides between the two scorers (0.771 for slide 1, 0.580 for slide 2, 0.682 for slide 3 and 
0.910 for slide 4) 
The mean, median and range of TILs percent of AV and HS scores in both the primary and 
recurrent tumours are displayed in supplementary table 4 A&B.  
No significant differences between slides representing various tumour blocks/areas were 
identified (inter-slide variation, p=0.251 for AV-TILs and p=0.162 for HS-TILs) (supplemen-
tary Figure 4). Moreover, our result showed that patients with the luminal A tumours were 
more homogenous in respect of inter-slide AV-TILs expression than other subtypes. When 
each slide was divided into four quadrants and each quadrant scored independently, the varia-
tion of TILs was statistically significant (intra-slide variation, p=0.019 for AV-TILs and 
p<0.0001 for HS-TILs).  Interestingly, recurrent tumours showed a trend towards lower TILs 
scores (p=0.052) and showed homogeneous TILs distribution when compared with their cor-
responding primary tumour (Figure 2). AV-TILs was higher in TNBC compared with other 
BC classes (p<0.001). Significant multiple correlations between AV-TILs and different im-
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mune cell subpopulations and between the immune cells markers were identified (all 
p<0.001).  
TILs (AV and HS) in primary BC were positively associated with higher tumour grade 
(p<0.001), tumour stages (p=0.038), poor NPI prognostic group (p<0.001), TNBC (p<0.001), 
and AR negative phenotypes (p=0.012). No significant association between TILs and patients 
age, tumour size, lymph node stage or LVI status was identified (Table 1).  TILs (AV and HS) 
showed a positive association with the grade in TNBC. Interestingly, within TNBC, AR posi-
tivity was associated with lower scores of TILs (p<0.001). No association was identified be-
tween TILs scores and basal-like phenotype as defined by basal cytokeratin and EGFR 17.  
Univariate survival analysis showed no significant association between TILs (AV and HS) 
and patient BCSS either in the whole cohort or those with local recurrence.  
High AV-TILs showed significant association with longer BCSS in TNBC patients (p=0.026), 
where distant metastasis developed in only 91 cases out of 230 cases. However, 61 cases of 
TNBC showed TILs associated with longer distant metastasis free survival (p=0.017) (Figure 
3). This was not observed in other BC subtype. Notably, survival analysis between treated 
and untreated patients (chemotherapy and endocrine therapy) did not show a significant asso-
ciation. However, in TNBC AV-TILs was a prognostic factor independent of adjuvant chemo-
therapy treatment. No significant association between HS-TILs and BCSS or DMFS was 
identified in any of BC subtypes. 
As AV-TILs was a significant predictor of outcome in TNBC, further analyses were limited to 
TNBC. Cox-proportional models including other prognostic parameters including patient age, 
tumour grade, and nodal stage showed that AV-TILs was an independent predictor for good 
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prognosis [p=0.004, HR 0.4, 95% CI 0.2– 0.8). In the model including TILs and various im-
mune cells (CD3, CD8, FOXP3, CD20 and CD68), only AV-TILs showed significant associa-
tion with patient outcome (supplementary Table 5). 
Testing the prognostic power of the combination of positive/negative TILs with high/low 
immune biomarker was performed, however there was no significant association in all breast 
cancer subtypes. Interestingly, in recurrent tumours, there was a significant association be-
tween high AV-TILs density and shorter post-recurrence patient survival (p=0.004) (Figure 
4).  
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DISCUSSION 
There is a growing interest in quantifying and reporting total TILs in BC and their different 
subpopulations in clinical practice due to their prognostic and possibly predictive value for 
immunotherapies 24, 25. In this study, a large cohort with long-term clinical follow-up was 
used to assess different immune cells infiltrate and their expression pattern in BC as well as 
correlating with patient outcome and tumour progression.  
The International TILs Working Group has reported that in most tumours, there is no obvious 
inter-slide heterogeneity (i.e. between multiple tissue sections from different tumour blocks 
of the same case) in TILs content at the morphological level.  However, no robust evidence to 
support this observational statement has yet been provided 7. To our knowledge, ours is the 
first study to assess TILs heterogeneity utilising multiple tumour tissue blocks from the same 
primary tumour and comparing these with their corresponding recurrence. For each sample in 
this study, TILs were assessed as average (AV-TILs) and hotspots (HS-TILs) to elaborate 
upon TILs distribution in different tumour areas. Our results showed no significant differ-
ences in the overall TILs scores between tumour blocks whether assessed as AV-TILs or HS-
TILs, indicating that any full-face H&E breast tumour tissue section is sufficient to evaluate 
TILs density within a whole tumour. However, when the analysis was limited to smaller tu-
mour areas as per different areas of the same slide (intra-slide heterogeneity), the difference 
in TILs scores were significant, particularly with regard to hotspots. 
 The latter finding represents the presence of substantial intra-slide heterogeneity and there-
fore underscores the variable nature of immune infiltrate within different tumour cells popu-
lation. This is consistent with earlier reports, where CD8, CD3, and CD20 expressing TILs 
subpopulations in core biopsies were more heterogeneous across the core compared with 
multiple cores from the same tumour 26. The variation of CD3, CD8 and CD20; were 30 
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-33% between the cores biopsy from same tumour while the higher variation 66-69% was in 
the same section27. Another study reported that spatial heterogeneity of TILs subtypes could 
play role in patient’s outcome. For instance, high CD3+ T lymphocytes in invasive margin is 
associated with disease free survival in BC, where high total and distance CD8+ T lympho-
cyte corresponded with better outcome in BC28. Both assessment methods of TILs; AV-TILs 
and HS-TILs, were significantly associated with other prognostic parameters in the whole 
cohort 28. 
 Interestingly, TILs showed lower proportions and were mostly homogenously distributed in 
recurrent tumours compared with their corresponding primary tumours. This is consistent 
with a previous report where lower expression of TILs in metastatic recurrences of TNBC 
and HER2 positive BC were observed compared to primary tumours 29. Moreover, signifi-
cantly shorter post-recurrence survival was observed in recurrent patients with dense TILs, 
providing evidence that assessment of TILs in recurrent tumours can be used as a prognostic 
variable to predict post-recurrence outcome. Of note, the recurrent tumours included all BC 
subtypes. Thus, the inverse association could be explained, at least in part, by the heterogene-
ity of BC and the variation of TILs interaction with primary and recurrent tumour as well the 
different subtypes.    
This study showed that TILs sub-populations were differently expressed in BC tumours 
where T-cells, as defined by CD3+ cells, appeared to dominate. This indicates that TILs are a 
heterogeneous mixture of different immune cell types that are most likely recruited to the tu-
mour vicinity to perform specific functions 30, 31. Additionally, our data showed that CD3, 
CD8, FOXP3, CD20 and CD68 were significantly associated with overall TILs, and TILs 
were higher in the more aggressive TNBC subtype than others. It has been reported that TILs 
assessed in H&E sections are significantly associated with CD20+ and CD45+ in BC32. The 
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high CD8+ and CD3+ cellular infiltrate showed a good prognosis and independent predictive 
value in TNBC regardless of other clinicopathological parameters. These findings are con-
cordant with the results reported by other studies 15, 33, 34. The higher CD20+ lymphocytes 
within the tumour were associated with better outcome in TNBC and HER2+. This may point 
to the higher immunogenicity of TNBC and HER2+ BC than luminal BC due to producing 
more B-cell antibodies against the tumour cell; results consistent with those reported by Buis-
seret and colleagues 35. Several subtypes of TNBC with their clinical relevance have been 
described with better outcome or treatment responses36. However, there was no significant 
association between FOXP3+ and patient outcome in TNBC. In contrast to our observations, 
Yeong et al reported that high density of intra tumoral FOXP3+ was associated with longer 
overall survival but not with stromal infiltration37 . In our study, lower TILs scores were ob-
served in the AR positive subclass of TNBC which is considered as prime candidates for anti-
androgen and CDK4/6 inhibition therapies 38, 39. However, no differential expression of TILs 
or various immune cell subtypes was observed with regard to sub-classification of TNBC into 
basal-like and non-basal-like groups 17.   
High expression of CD68 was significantly associated with worse outcome in patients with 
luminal B tumours, which may explain, at least in part, the distinct roles of TILs sub-popula-
tion in different BC subtypes 40. These results also underscore a distinct tumour stromal inter-
actions in TNBC compared to non-TNBC tumours as evidenced by their different inflamma-
tory microenvironment. The tumour association macrophage differentiates to active classic 
(M1) and alternative (M2) where the latter is associated with growth, angiogenesis, migration 
and invasion of a diversity of cancers41. 
The significant association of AV-TILs with different lymphocyte subtypes and its indepen-
dent association with outcome in this study signify the reliability of AV-TILs as assessed on 
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H&E stained sections for accurate immune cell scoring as a prognostic parameter in BC. CD3 
and CD8 lost their prognostic effect when they were included in the same model. This pro-
vides evidence for the utility of prognostic value of AV-TILs assessment in H&E stained sec-
tions, particularly in TNBC.  
In conclusion, TILs infiltrate is significantly different between TNBC and non-TNBC with 
distinct subpopulations of immune cells in the former. This might explain the different prog-
nostic utility of TILs infiltrate and the immune cells subtypes in BC. Although the In-
ternational TILs International Working Group have recognised heterogeneity as an issue, no 
data is available to provide any strong guidance. Our result confirms that average TILs as-
sessment using one representative tumour block can reliably report on TILs infiltrate across a 
whole breast tumour. Assessing average TILs score using H&E slides not only provides re-
producible and independent prognostic information in TNBC but is also equivalent to im-
munohistochemically defined subpopulations of immune cells. The role of B-lymphocytes 
and histiocytes in BC biology and prognosis as well as the association between TILs and the 
outcome in the recurrent tumour, warrant further investigation.  
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Legends of the figures  
Figure 1 Representative photomicrographs of the expression of immune cell markers (CD3, 
CD8, FOXP3, CD20, and CD68)  
Figure 2 Representative photomicrographs of the difference between tumour proportions of 
TILs infiltrate in the same case for primary (A, B) and its corresponding recurrent tumour (C, 
D) 
Figure 3: Kaplan Meier survival plots for  average TILs % expression in triple negative 
breast cancer for A) breast cancer specific survival (BCSS) & B) Distant Metastasis Free 
Survival (DMFS) 
Figure 4: Kaplan Meier survival plots for TILs % expression in recurrent breast cancer show-
ing the post-recurrence survival 
!17
References 
1. Place AE, Jin Huh S, Polyak K. The microenvironment in breast cancer progres-
sion: Biology and implications for treatment. Breast cancer research : BCR 
2011;13;227. 
2. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nature re-
views. Cancer 2009;9;239-252. 
3. Tian T, Ruan M, Yang W, Shui R. Evaluation of the prognostic value of tumor-infil-
trating lymphocytes in triple-negative breast cancers. Oncotarget 2016;7;44395-44405. 
4. Hida AI, Sagara Y, Yotsumoto D et al. Prognostic and predictive impacts of tumor-
infiltrating lymphocytes differ between triple-negative and her2-positive breast cancers 
treated with standard systemic therapies. Breast Cancer Res Treat 2016;158;1-9. 
5. Loi S, Michiels S, Salgado R et al. Tumor infiltrating lymphocytes are prognostic in 
triple negative breast cancer and predictive for trastuzumab benefit in early breast can-
cer: Results from the finher trial. Ann Oncol 2014;25;1544-1550. 
6. Adams S, Gray RJ, Demaria S et al. Prognostic value of tumor-infiltrating lympho-
cytes in triple-negative breast cancers from two phase iii randomized adjuvant breast 
cancer trials: Ecog 2197 and ecog 1199. J Clin Oncol 2014;32;2959-2966. 
7. Salgado R, Denkert C, Demaria S et al. The evaluation of tumor-infiltrating lym-
phocytes (tils) in breast cancer: Recommendations by an international tils working group 
2014. Ann Oncol 2015;26;259-271. 
8. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and 
metastasis. Nature medicine 2013;19;1423-1437. 
9. Wakabayashi O, Yamazaki K, Oizumi S et al. Cd4+ t cells in cancer stroma, not 
cd8+ t cells in cancer cell nests, are associated with favorable prognosis in human non-
small cell lung cancers. Cancer Sci 2003;94;1003-1009. 
10. Liu S, Lachapelle J, Leung S, Gao D, Foulkes WD, Nielsen TO. Cd8+ lymphocyte 
infiltration is an independent favorable prognostic indicator in basal-like breast cancer. 
Breast cancer research : BCR 2012;14;R48. 
11. Bailey SR, Nelson MH, Himes RA, Li Z, Mehrotra S, Paulos CM. Th17 cells in can-
cer: The ultimate identity crisis. Frontiers in immunology 2014;5;276. 
12. DeNardo DG, Coussens LM. Inflammation and breast cancer. Balancing immune 
response: Crosstalk between adaptive and innate immune cells during breast cancer 
progression. Breast cancer research : BCR 2007;9;212-212. 
13. Mahmoud SM, Paish EC, Powe DG et al. Tumor-infiltrating cd8+ lymphocytes pre-
dict clinical outcome in breast cancer. Journal of clinical oncology : official journal of the 
American Society of Clinical Oncology 2011;29;1949-1955. 
14. Mahmoud SM, Paish EC, Powe DG et al. An evaluation of the clinical significance 
of foxp3+ infiltrating cells in human breast cancer. Breast cancer research and treatment 
2011;127;99-108. 
15. Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Ellis IO, Green AR. The prognostic 
significance of b lymphocytes in invasive carcinoma of the breast. Breast Cancer Res 
Treat 2012;132;545-553. 
16. Aleskandarany MA, Abduljabbar R, Ashankyty I et al. Prognostic significance of 
androgen receptor expression in invasive breast cancer: Transcriptomic and protein ex-
pression analysis. Breast Cancer Res Treat 2016;159;215-227. 
17. Rakha EA, Elsheikh SE, Aleskandarany MA et al. Triple-negative breast cancer: 
Distinguishing between basal and nonbasal subtypes. Clin Cancer Res 
2009;15;2302-2310. 
18. Hida AI, Sagara Y, Yotsumoto D et al. Prognostic and predictive impacts of tumor-
infiltrating lymphocytes differ between triple-negative and her2-positive breast cancers 
treated with standard systemic therapies. Breast Cancer Research and Treatment 
2016;158;1-9. 
19. Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Ellis IO, Green AR. Tumour-infil-
trating macrophages and clinical outcome in breast cancer. Journal of clinical pathology 
2012;65;159-163. 
!18
20. Garcia-Caballero T, Grabau D, Green AR et al. Determination of her2 amplification 
in primary breast cancer using dual-colour chromogenic in situ hybridization is compara-
ble to fluorescence in situ hybridization: A european multicentre study involving 168 
specimens. Histopathology 2010;56;472-480. 
21. El Ansari R, Craze ML, Miligy I et al. The amino acid transporter slc7a5 confers a 
poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic 
target in luminal b tumours. Breast cancer research : BCR 2018;20;21. 
22. Green AR, Aleskandarany MA, Agarwal D et al. Myc functions are specific in bio-
logical subtypes of breast cancer and confers resistance to endocrine therapy in luminal 
tumours. British journal of cancer 2016;114;917-928. 
23. Abd El-Rehim DM, Ball G, Pinder SE et al. High-throughput protein expression 
analysis using tissue microarray technology of a large well-characterised series identifies 
biologically distinct classes of breast cancer confirming recent cdna expression analyses. 
International journal of cancer 2005;116;340-350. 
24. Stanton SE, Disis ML. Clinical significance of tumor-infiltrating lymphocytes in 
breast cancer. J Immunother Cancer 2016;4;59. 
25. Wang K, Xu J, Zhang T, Xue D. Tumor-infiltrating lymphocytes in breast cancer 
predict the response to chemotherapy and survival outcome: A meta-analysis. Oncotar-
get 2016;7;44288-44298. 
26. Brown JR, Wimberly H, Lannin DR, Nixon C, Rimm DL, Bossuyt V. Multiplexed 
quantitative analysis of cd3, cd8, and cd20 predicts response to neoadjuvant chemo-
therapy in breast cancer. Clinical cancer research : an official journal of the American As-
sociation for Cancer Research 2014;20;5995-6005. 
27. Mani NL, Schalper KA, Hatzis C et al. Quantitative assessment of the spatial het-
erogeneity of tumor-infiltrating lymphocytes in breast cancer. Breast cancer research : 
BCR 2016;18;78. 
28. Nawaz S, Heindl A, Koelble K, Yuan Y. Beyond immune density: Critical role of 
spatial heterogeneity in estrogen receptor-negative breast cancer. Modern pathology : an 
official journal of the United States and Canadian Academy of Pathology, Inc 
2015;28;1621. 
29. Ogiya R, Niikura N, Kumaki N et al. Comparison of tumor-infiltrating lymphocytes 
between primary and metastatic tumors in breast cancer patients. Cancer science 
2016;107;1730-1735. 
30. Oelkrug C, Ramage JM. Enhancement of t cell recruitment and infiltration into 
tumours. Clinical and experimental immunology 2014;178;1-8. 
31. Zhang Y, Gallastegui N, Rosenblatt JD. Regulatory b cells in anti-tumor immunity. 
International immunology 2015;27;521-530. 
32. Buisseret L, Desmedt C, Garaud S et al. Reliability of tumor-infiltrating lympho-
cyte and tertiary lymphoid structure assessment in human breast cancer. Modern pathol-
ogy : an official journal of the United States and Canadian Academy of Pathology, Inc 
2017;30;1204-1212. 
33. Sikandar B, Qureshi MA, Naseem S, Khan S, Mirza T. Increased tumour infiltration 
of cd4+ and cd8+ t-lymphocytes in patients with triple negative breast cancer suggests 
susceptibility to immune therapy. Asian Pac J Cancer Prev 2017;18;1827-1832. 
34. Denkert C, Loibl S, Noske A et al. Tumor-associated lymphocytes as an indepen-
dent predictor of response to neoadjuvant chemotherapy in breast cancer. Journal of 
clinical oncology : official journal of the American Society of Clinical Oncology 
2010;28;105-113. 
35. García-Teijido P, Cabal ML, Fernández IP, Pérez YF. Tumor-infiltrating lymphocytes 
in triple negative breast cancer: The future of immune targeting. Clinical Medicine In-
sights. Oncology 2016;10;31-39. 
36. Burstein MD, Tsimelzon A, Poage GM et al. Comprehensive genomic analysis iden-
tifies novel subtypes and targets of triple-negative breast cancer. Clinical cancer research 
: an official journal of the American Association for Cancer Research 
2015;21;1688-1698. 
37. Yeong J, Thike AA, Lim JC et al. Higher densities of foxp3(+) regulatory t cells are 
associated with better prognosis in triple-negative breast cancer. Breast Cancer Res 
Treat 2017;163;21-35. 
!19
38. Barton VN, Gordon MA, Richer JK, Elias A. Anti-androgen therapy in triple-nega-
tive breast cancer. Therapeutic Advances in Medical Oncology 2016;8;305-308. 
39. Mina A, Yoder R, Sharma P. Targeting the androgen receptor in triple-negative 
breast cancer: Current perspectives. OncoTargets and therapy 2017;10;4675-4685. 
40. Medrek C, Ponten F, Jirstrom K, Leandersson K. The presence of tumor associated 
macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC 
cancer 2012;12;306. 
41. Yang J, Li X, Liu X, Liu Y. The role of tumor-associated macrophages in breast car-
cinoma invasion and metastasis. International Journal of Clinical and Experimental 
Pathology 2015;8;6656-6664. 
!20
Table 1:  Associations of tumour infiltrating lymphocytes (Average TILs) and 
clinicopathological parameters in breast cancer (n=230) 
Parameters Whole cohort 
(n=1165)
TILs H&E subgroup (n=230)
N (%) Low TILs
No. (%)
High TILs 
No. (%)
χ2 
p-value
Patient Age (Years)
   < 50  
   ≥ 50
818(66.0) 
421(34.0)
44 (37.9) 
31 (27.4)
72 (62.1) 
82 (72.6)
2.9 
0.091
Tumour size (cm) 
   < 2 
   ≥ 2
600(48.8) 
630(51.2)
44 (28.6) 
31 (41.3)
110 (71.4) 
44 (58.7)
3.7 
0.038
Lympho-vascular Invasion
   Negative 
   Positive
855(69.7) 
855(69.7)
52 (34.9) 
23 (28.8)
97(65.1) 
57(71.3)
0.9 
0.344
Tumour Grade
   Grade I 
   Grade II 
   Grade III
257(19.6) 
443(33.7) 
612(46.6)
12 (75.0) 
19 (55.9) 
43 (24.2)
4 (25.0) 
15 (44.1) 
135 (75.8)
27.3 
<0.001
Axillary nodal stage * 
   Stage I 
   Stage II 
   Stage III
897(66.5) 
357(26.5) 
94(7.0)
53 (37.9) 
17 (28.3) 
4 (14.3)
87 (62.1) 
43 (71.7) 
24 (85.7)
6.5 
0.038
Nottingham Prognostic 
Index
   Good Prognostic Group 
   Moderate Prognostic 
Group 
   Poor Prognostic Group
187(15.2) 
629(51.1) 
414(33.7)
9 (15.8) 
49 (33.3) 
17 (68.0)
48 (84.2) 
98 (66.7) 
8 (32.0)
21.6 
<0.001
Oestrogen Receptor
   Negative 
   Positive
329(25.3) 
973(74.7)
36 (21.8) 
39 (60.9)
129 (78.2) 
25 (39.1)
32.1 
<0.001
Progesterone Receptor
   Negative 
   Positive
483(40.6) 
708(59.4)
43 (24.2) 
32 (62.7)
135 (75.8) 
19 (37.3)
26.8 
<0.001 
HER2 status
   Negative 
   Positive
1063(73.2) 
135(9.3)
69 (32.5) 
5 (31.3) 143 (67.5) 
11 (68.8)
0.1 
0.915
Triple negative status
   Non-triple negative 
   Triple negative
1052(83.2) 
213(16.8)
41 (55.4) 
33 (21.44) 33 (44.6) 
121 (78.6)
26.3 
<0.001 
* Nodal status based on Nottingham system nodal stage (1 for node negative, 2 = 1-3 
nodes positive, and 3  ≥ 4 nodes positive).


Supplementary Table 1: Antibodies used in immunohistochemistry.  
Supplementary Table 2: Mean, median and range, of immune cell subtypes counts/core diameter assessed as absolute number of cells (in the 
whole series and in different BC molecular subtypes). 
Antibody Clone Dilution Antigen retrieval Source
CD3 SP7 1:100 Microwave in EDTA Vector laboratories 
CD8 1A5 1:50 Microwave in citrate Vector laboratories
FOXP3 23A/E7 1:100 Microwave in EDTA Abcam
CD20 L26 1:300 Microwave in citrate Dako
CD68 KP1 1:300 Microwave in citrate Dako
Stromal 
immune cell 
density/
core 
diameter 
Whole series Luminal A Luminal B HER2 enriched Triple negative
Mean Median Range Mean Median Range Mean Median Range Mean Median Range Mean Median Range
CD3+  55 33 0-450 34 22 0-258 44 25 0-317 73 51 0-425 93 67 0-450
CD8+ 25 11 0-242 16 8 0-142 22 10 0-317 31 17 0-173 40 23 0-242
FOXP3+ 14 7 0-153 6 2 0-55 11 5 0-68 19 13 0-153 27 21 1-128
CD20+ 13 1 0-415 7 0 0-211 11 1 0-253 22 3 0-415 24 5 0-255
CD68+ 32 24 0-252 18 15 0-150 28 23 1-215 38 32 3-252 51 42 1-225
Supplementary Table 3: Multivariate Cox regression hazard model including other prognostic clinicopathological parameters shows that 
average TILs as well as immunohistochemically defined CD3+ or CD8+ T-lymphocytes provided an independent prognostic value; associated 
with longer breast cancer specific survival in the subset of triple negative breast cancer. 
Variable Hazard ratio 95% Confidence Interval (CI) p- value
Lower Upper
Patient Age 0.7 0.6 4.2 0.169
Tumour Grade 2.9 1.1 3.1 0.134
 Node Stage 2.0 0.5 2.2 <0.001
Tumour Size 1.3 0.7 2.3 0.291
TILs-AV 0.4 0.2 0.7 0.004
Patient Age 0.6 0.4 1.0 0.055
Tumour Grade 1.9 0.6 5.8 0.252
 Node Stage 1.7 1.2 2.2 <0.001
Tumour Size 1.5 0.9 2.4 0.081
CD8+ 0.4 0.2 0.7 0.002
Patient Age 0.6 0.4 1.0 0.08
Tumour Grade 1.4 0.7 3.2 0.998
  
Supplementary table 4A: Mean, median and range of %TILs in primary and their corresponding recurrence in subset of study cohort (n=44) 
 Node Stage 1.6 1.2 2.1 0.001
Tumour Size 1.4 0.9 2.3 0.097
CD3+ 0.3 0.1 0.6 0.003
% of stromal 
TILS/tumour
Primary tumour Recurrent tumour 
Mean Median Range Mean Median Range
AV-TILs 
HS-TILs
22 
38
15 
28
1-80 
1-90
9 
13
5 
7
1-45 
1-60
Supplementary table 4B: Mean, median and range of %TILs in different breast cancer molecular subtype  
% of stromal 
TILS/tumour
Luminal A Luminal B HER2 enriched Triple negative
Mean Median Range Mean Median Range Mean Median Range Mean Median Range
AV-TILs 
AV-TILs 
HS-TILs
8 
16
5 
8
1-40 
2-90
12 
22
10 
12
3-40 
3-90
16 
33
12 
20
5-50 
6-90
27 
45
25 
40
1-85 
1-90
Supplementary table 5: Multivariate Cox regression hazard model including average TILs and various immunohistochemically defined 
immune cell subtypes shows that average TILs is the only independent prognostic parameter associated with longer breast cancer specific 
survival in the subset of triple negative breast cancer 
Variable Hazard ratio
95%CI
p-value
Lower Upper
CD3+ 0.6 0.1 2.8 0.487
CD8+ 0.5 0.2 1.1 0.088
FOXP3+ 1.8 0.5 6.1 0.313
CD20+ 1.1 0.5 2.5 0.724
CD68+ 2.3 0.7 7.5 0.140
AV-TILs 0.3 0.1 0.8 0.023

Supplementary figures 
  
Supplementary figure 1: Kaplan Meier survival plots (A &B) showing association between 
FOXP3+ and CD68+ in and breast cancer specific survival (BCSS)  
 
supplementary figure 2a: Kaplan Meier survival plots showing association between CD3+ 
lymphocytes’ density in triple negative breast cancer and A) BCSS & B) Distant Metastasis 
Free Survival (DMFS) 
  
Supplementary figure 2b: Kaplan Meier survival plots for showing association between 
CD8+ lymphocytes’ density in triple negative breast cancer and A) BCSS & B) DMFS. 
 
Supplementary figure 2c: Kaplan Meier survival plots for showing association between 
CD20+ lymphocytes density in triple negative breast cancer and A) BCSS & B) DMFS. 
 
Supplementary figure 3: A) Kaplan Meier survival plots showing association between 
CD68+ histiocytes’ density in luminal B breast cancer subtype B) CD20+ lymphocytes’ 
density in HER2+ enriched breast cancer and BCSS. 
  
 
Supplementary figure 4 shows average TILs & hotspot TILs scores in multiple tumour 
blocks. S1, 2, 3 & 4 are sections 1, 2, 3, & 4 from four different tumour blocks 
